Bluejay Diagnostics Inc (BJDX) - Net Assets
Based on the latest financial reports, Bluejay Diagnostics Inc (BJDX) has net assets worth $5.98 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.12 Million) and total liabilities ($1.14 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read BJDX liabilities breakdown for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.98 Million |
| % of Total Assets | 83.93% |
| Annual Growth Rate | N/A |
| 5-Year Change | -70.68% |
| 10-Year Change | N/A |
| Growth Volatility | 65.26 |
Bluejay Diagnostics Inc - Net Assets Trend (2019–2025)
This chart illustrates how Bluejay Diagnostics Inc's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Bluejay Diagnostics Inc for the complete picture of this company's asset base.
Annual Net Assets for Bluejay Diagnostics Inc (2019–2025)
The table below shows the annual net assets of Bluejay Diagnostics Inc from 2019 to 2025. For live valuation and market cap data, see how much is Bluejay Diagnostics Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $5.98 Million | +4.29% |
| 2024-12-31 | $5.73 Million | +97.92% |
| 2023-12-31 | $2.89 Million | -74.92% |
| 2022-12-31 | $11.54 Million | -43.37% |
| 2021-12-31 | $20.38 Million | +584.57% |
| 2020-12-31 | $-4.21 Million | -43.44% |
| 2019-12-31 | $-2.93 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bluejay Diagnostics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3858451400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $60.00 | 0.00% |
| Other Components | $47.49 Million | 794.82% |
| Total Equity | $5.98 Million | 100.00% |
Bluejay Diagnostics Inc Competitors by Market Cap
The table below lists competitors of Bluejay Diagnostics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TCI Finance Limited
NSE:TCIFINANCE
|
$1.99 Million |
|
Ion Energy Ltd
V:ION
|
$1.99 Million |
|
Jadestone Energy Inc
LSE:JSE
|
$1.99 Million |
|
Aclarion Inc
NASDAQ:ACON
|
$1.99 Million |
|
Tessin Nordic Holding AB
ST:TESSIN
|
$1.99 Million |
|
Kancera AB (publ)
ST:KAN
|
$1.98 Million |
|
MEP Infrastructure Developers Limited
NSE:MEP
|
$1.98 Million |
|
EF EnergyFunders Ventures Inc
V:EFV
|
$1.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bluejay Diagnostics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,729,499 to 5,975,289, a change of 245,790 (4.3%).
- Net loss of 6,848,483 reduced equity.
- New share issuances of 8,346,692 increased equity.
- Other factors decreased equity by 1,252,419.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.85 Million | -114.61% |
| Share Issuances | $8.35 Million | +139.69% |
| Other Changes | $-1.25 Million | -20.96% |
| Total Change | $- | 4.29% |
Book Value vs Market Value Analysis
This analysis compares Bluejay Diagnostics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.14x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-147.84 | $1.92 | x |
| 2020-12-31 | $-212.06 | $1.92 | x |
| 2021-12-31 | $648.58 | $1.92 | x |
| 2022-12-31 | $366.32 | $1.92 | x |
| 2023-12-31 | $84.48 | $1.92 | x |
| 2024-12-31 | $124.97 | $1.92 | x |
| 2025-12-31 | $13.31 | $1.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bluejay Diagnostics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -114.61%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.19x
- Recent ROE (-114.61%) is below the historical average (-98.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-464.47K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-705.10K |
| 2021 | -18.30% | -4972914.67% | 0.00x | 1.03x | $-5.77 Million |
| 2022 | -80.55% | -3733.11% | 0.02x | 1.17x | $-10.45 Million |
| 2023 | -343.85% | 0.00% | 0.00x | 1.68x | $-10.24 Million |
| 2024 | -134.70% | 0.00% | 0.00x | 1.16x | $-8.29 Million |
| 2025 | -114.61% | 0.00% | 0.00x | 1.19x | $-7.45 Million |
Industry Comparison
This section compares Bluejay Diagnostics Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bluejay Diagnostics Inc (BJDX) | $5.98 Million | 0.00% | 0.19x | $1.99 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About Bluejay Diagnostics Inc
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoas… Read more